1GERN.MI
GERON CORP
€1.53
+0.00%
2026-02-26
About GERON CORP
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
Key Fundamentals
EPS (TTM)
€-0.09
ROE
-27.1%
Revenue Growth (YoY)
30.9%
Profit Margin
-34.3%
Debt/Equity
53.28
Price/Book
3.51
Beta
0.68
Market Cap
€689.0M
Avg Volume (10D)
2K
Recent Breakout Signals
No recent breakout signals detected for 1GERN.MI.
Recent Price Range (60 Days)
60D High
€1.58
60D Low
€1.01
Avg Volume
1K
Latest Close
€1.53
Get breakout alerts for 1GERN.MI
Sign up for Breakout Scanner to receive daily notifications when 1GERN.MI triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
GERON CORP (1GERN.MI) is listed on the Borsa Italiana (MIL). Breakout Scanner monitors 1GERN.MI daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. 1GERN.MI operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.